Maintenance of clinical response and consistent safety profile with up to 3 years of continuous treatment with guselkumab: Results from the VOYAGE 1 and VOYAGE 2 trials — Kristian Reich (2019) | RDL Network
Maintenance of clinical response and consistent safety profile with up to 3 years of continuous treatment with guselkumab: Results from the VOYAGE 1 and VOYAGE 2 trials
April W. Armstrong, Kilian Eyerich, Curdin Conrad, Yihong Zhu, Ya‐Wen Yang, Megan Miller, Yin You, Yaung‐Kaung Shen, Peter Foley, Christopher Em Griffiths, Bruce Strober
Andrew Blauvelt, C. Leonardi, Boni E. Elewski, Jeffrey Crowley, Lyn Guenther, Melinda Gooderham, Richard G. Langley, Ronald Vender, Andreas Pinter, Christopher Em Griffiths, Yayoi Tada, Hany Elmaraghy, Renata Gontijo Lima, Gaia Gallo, L. Renda, Russel Burge, S.Y. Park, Baojin Zhu, Kim Papp
.webp){kind=small}
Discussion(0)
No comments yet. Be the first to comment.